AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Hypospadias and endocrine disruption: is there a connection? (Children's Health Review).

Environmental Health Perspectives

| November 01, 2001 | Baskin, Laurence S.; Himes, Katherine; Colborn, Theodora E. | COPYRIGHT 2001 National Institute of Environmental Health Sciences. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan.  All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

Hypospadias is one of the most common congenital anomalies in the United States, occurring in approximately 1 in 250 newborns or roughly 1 in 125 live male births. It is the result of arrested development of the urethra, foreskin, and ventral surface of the penis where the urethral opening may be anywhere along the shaft, within the scrotum, or in the perineum. The only treatment is surgery. Thus, prevention is imperative. To accomplish this, it is necessary to determine the etiology of hypospadias, the majority of which have been classified as idiopathic. In this paper we briefly describe the normal development of the male external genitalia and review the prevalence, etiology, risk factors, and epidemiology of hypospadias. The majority of hypospadias are believed to have a multifactorial etiology, although a small percentage do result from single gene mutations. Recent findings suggest that some hypospadias could be the result of disrupted gene expression. Discoveries about the antiandrogenic mechanisms of action of some contemporary-use chemicals have provided new knowledge about the organization and development of the urogenital system and may provide additional insight into the etiology of hypospadias and direction for prevention. Key words: antiandrogens, differentiation, external genitalia, gene expression, urogenital development. Environ Health Perspect 109:1175-1183 (2001). [Online 7 November 2001] http://ehpnet1.niehs.nih.gov/docs/2001/109p1175-1183baskin/abstract.html

Hypospadias is one of the most common congenital anomalies in the United States; it occurs in approximately 1 in 250 newborns or roughly 1 in 125 live male births (1,2). Hypospadias can be defined as an arrest in normal development of the urethral, foreskin, and ventral aspect of the penis. This results in a wide range of abnormalities, with the urethral opening being anywhere along the shaft of the penis, within the scrotum, or even in the perineum (3). The more severe forms of hypospadias are associated with penile curvature. Left uncorrected, patients with severe hypospadias may need to sit down to void and tend to shun intimate relationships because of the fears related to abnormal sexuality. Babies born with severe hypospadias and penile curvature may have "ambiguous genitalia" in the newborn period, making an immediate accurate sex assignment difficult.

The only treatment for hypospadias is surgical repair of the anatomical defect (3). Reconstruction, if performed by an experienced surgeon, generally involves a single outpatient procedure (3,4). Occasionally, however, extensive surgery is required, or patients may face "redo" surgeries to improve suboptimal results (5). There is significant morbidity associated with some surgical procedures to correct hypospadias as well as potential psychosocial consequences of having an abnormal genital (6,7). In addition to the difficulty of surgery, the emotional and physical stress for the parents of patients with ambiguous genitalia must be considered (8).

In this paper we explore the hypothesis that hypospadias may in part be the result of exposure to synthetic and/or natural chemicals that can perturb normal male development. The fetus is especially sensitive to these chemicals known as endocrine disruptors that can mimic or interfere with the natural hormones that control development. We provide a brief description of normal development of the male external genitalia and review the prevalence, etiology, risk factors, and epidemiology of hypospadias. We also present evidence concerning the effects of recently discovered xenobiotic antiandrogens on the development of the male urogenital system.

Classification of Hypospadias

Related articles from newspapers, magazines, journals, and more
Ultrasound of the urogenital system.(Brief Article)(Book Review)
Magazine article from: SciTech Book News September 1, 2006 700+ words
1588902374 Ultrasound of the urogenital system. Baxter, Grant M. and Paul S. Sidhu. Thieme Medical...use of ultrasound imaging in the investigation of the urogenital system. The entire renal tract is covered, along with the prostate...
urogenital system
Reference information from: The Mosby Medical Encyclopedia October 1, 1996 700+ words
The Mosby Medical Encyclopedia 10-01-1996 urogenital system, the urinary and genital organs and the structures that develop in the fetus to form the kidneys, the ureters, the bladder...
Oxybutynin.(Urogenital system)(Brief Article)
MPR Monthly Prescribing Reference October 1, 2005 700+ words
Oxybutynin (Anturol, from Antares) a transdermal gel formulation of this antispasmodic/anticholinergic for treating overactive bladder--Phase 2
Oxybutynin gel.(Urogenital system)(drug use)(Brief article)
Nurse Practitioners' Prescribing Reference March 22, 2006 700+ words
Oxybutynin gel (Anturol, from Antares) an antispasmodic/anticholinergic being developed in a gel formulation for the treatment of overactive bladder--Phase 3
Section 19: urogenital system.
MPR Monthly Prescribing Reference October 1, 2005 700+ words
SECTION 19 19A Urinary tract disorders PRESCRIBING NOTES For antibiotics and antiinfectives for treating urinary tract infections see Section 11A. AZO STANDARD OTC PolyMedica Urinary tract analgesic. Phenazopyridine HCl 95mg; tabs. Indications: Urinary tract discomfort. Adults: 190mg 3 times daily
19B Incontinence/enuresis.(UROGENITAL SYSTEM)
Physician Assistants' Prescribing Reference December 22, 2005 700+ words
DDAVP Sanofi Aventis Rx Vasopressin (synthetic). Desmopressin acetate 0.1mg, 0.2mg; scored tabs. Indications: Primary nocturnal enuresis. Adults and Children: <6yrs: not recommended. 6-17yrs: initially 0.2mg once daily at bedtime; individualize; max 0.6mg. When switching to tabs give 1st oral
19D Erectile dysfunction.(UROGENITAL SYSTEM)
Physician Assistants' Prescribing Reference December 22, 2005 700+ words
CAVERJECT pharmacia Rx Prostaglandin. Alprostadil 5micrograms, 10micrograms, 20micrograms, 40micrograms; per vial; pwd for intracavernous inj after reconstitution. indications: Treatment and diagnosis of erectile dysfunction. Adults: Inject into the dorso-lateral aspect of the proximal third of
Incontinence/enuresis.(SECTION 19: UROGENITAL SYSTEM)
MPR Monthly Prescribing Reference November 1, 2005 700+ words
DDAVP Sanofi Aventis Rx Vasopressin (synthetic). Desmopressin acetate 0.1mg, 0.2mg; scored tabs. Indications: Primary nocturnal enuresis. Adults and Children: <6yrs: not recommended. 6-17yrs: initially 0.2mg once daily at bedtime; individualize; max 0.6mg. When switching to tabs give is, oral
For more facts and information, see all results
©2009 Gale, a part of Cengage Learning. All rights reserved.
About us | FAQs | Contact us | Privacy policy | Terms and conditions
Other Gale sites: Encyclopedia.com | HighBeam Research | Acquire Content | Books & Authors | Goliath | MovieRetriever | Smart QandA